

Dirk Arnold

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4945493/dirk-arnold-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

4,629
citations

30
h-index

67
g-index

124
ext. papers

5,334
ext. citations

5.2
avg, IF

4.86
L-index

#	Paper	IF	Citations
107	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 29-37	21.7	818
106	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 679-87	21.7	484
105	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 979-89	21.7	432
104	Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. <i>JAMA Oncology</i> , 2017 , 3, 1237-1244	13.4	175
103	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1355-69	21.7	173
102	Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 110-7	2.2	165
101	Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5910-7	2.2	127
100	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015 , 15, 564	4.8	125
99	Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 1081-6	4	119
98	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 111, 330-9	5.3	116
97	Skeletal muscle metastases: primary tumours, prevalence, and radiological features. <i>European Radiology</i> , 2010 , 20, 649-58	8	111
96	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015 , 51, 271-81	7.5	80
95	Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. <i>Anti-Cancer Drugs</i> , 2000 , 11, 635-8	2.4	70
94	Anti-angiogenic therapies for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2009 , CD005392	5.2	69
93	Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). <i>BMC Cancer</i> , 2014 ,	4.8	68
92	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1415-24	4.9	67
91	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. <i>European Journal of Cancer</i> , 2016 , 63, 11-24	7.5	63

90	Oxaliplatin: a review of approved uses. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 125-37	4	57
89	Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 472-8	4	49
88	Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 3469-77	12.9	48
87	Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. <i>BMC Cancer</i> , 2010 , 10, 86	4.8	48
86	Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. <i>BMC Cancer</i> , 2010 , 10, 309	4.8	44
85	Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2017 , 140, 2134-2144	7.5	40
84	EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 5161-9	12.9	39
83	Targeted treatments in colorectal cancer: state of the art and future perspectives. <i>Gut</i> , 2010 , 59, 838-5819.2	38	
82	A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. <i>BMC Cancer</i> , 2013 , 13, 67	4.8	37
81	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , 2016 , 11, 383-400	5	33
80	ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 110, 81-93	7	32
79	Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2013 , 8, 90	4.2	32
78	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 991-1006	31	
77	Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. <i>Deutsches A&#x0308;rzteblatt International</i> , 2011 , 108, 802-8	2.5	30
76	Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. <i>Cancer Investigation</i> , 2010 , 28, 856-64	2.1	30
75	Update on capecitabine in colorectal cancer. <i>Oncologist</i> , 2006 , 11, 1003-9	5.7	30
74	Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 285-296	3.8	27
73	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. <i>Oncologist</i> , 2006 , 11, 602-11	5.7	27

72	Prevalence and patterns of renal involvement in imaging of malignant lymphoproliferative diseases. <i>Acta Radiologica</i> , 2012 , 53, 343-8	2	26
71	Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 110, 189-94	5.3	25
70	Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?. <i>Strahlentherapie Und Onkologie</i> , 2010 , 186, 658-64	4.3	24
69	Intramuscular manifestation of non-Hodgkin lymphoma and myeloma: prevalence, clinical signs, and computed tomography features. <i>Acta Radiologica</i> , 2010 , 51, 47-51	2	23
68	Breast plasmacytoma. <i>Acta Radiologica</i> , 2010 , 51, 498-504	2	22
67	Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. <i>Deutsches A&#x0308;rzteblatt International</i> , 2009 , 106, 843-8	2.5	21
66	Port catheter insufficiency: incidence and clinical-radiological correlations. <i>Onkologie</i> , 2008 , 31, 455-61		21
65	The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2000 , 11, 771-86	2.4	20
64	Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. <i>BMC Cancer</i> , 2012 , 12, 356	4.8	19
63	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. <i>European Journal of Cancer</i> , 2015 , 51, 18-26	7.5	18
62	Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 992-9	4	18
61	New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. <i>Drugs</i> , 2013 , 73, 883-91	12.1	18
60	Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2016 , 15, e29-39	3.8	15
59	Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. <i>Acta Oncologica</i> , 2014 , 53, 392-8	3.2	15
58	PTEN deletion is rare but often homogeneous in gastric cancer. <i>Journal of Clinical Pathology</i> , 2012 , 65, 693-8	3.9	15
57	Central venous catheter complications during home parenteral nutrition: a prospective pilot study of 481 patients with more than 30,000 catheter days. <i>Oncology Research and Treatment</i> , 2008 , 31, 605-9	2.8	15
56	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). <i>Journal of Clinical Oncology</i> , 2014 , 32, 3503-3503	2.2	15
55	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. <i>European Journal of Cancer</i> , 2018 , 101, 105-113	7.5	14

54	The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study. <i>Clinical Cancer Research</i> , 2014 , 20, 3348-57	12.9	14
53	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019 , 145, 2282-2291	7.5	13
52	Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. <i>Acta Oncologica</i> , 2015 , 54, 171-8	3.2	13
51	Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. <i>Clinical Epidemiology</i> , 2015 , 7, 295-303	5.9	13
50	Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. <i>BMC Cancer</i> , 2014 , 14, 761	4.8	13
49	Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 161-74	5.4	13
48	A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. <i>Gastric Cancer</i> , 2015 , 18, 833-42	7.6	12
47	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1477-93	3.5	12
46	Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). <i>Oncology Research and Treatment</i> , 2006 , 29, 563-7	2.8	12
45	MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1197-1204	4.9	11
44	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial. <i>Frontiers in Oncology</i> , 2018 , 8, 474	5.3	11
43	Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. <i>Oncology Research and Treatment</i> , 2015 , 38, 300-8	2.8	10
42	Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. <i>BMC Cancer</i> , 2016 , 16, 82	4.8	10
41	Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. <i>BMC Cancer</i> , 2012 , 12, 349	4.8	10
40	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017 , 117, 1768-1776	8.7	8
39	A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. <i>Oncology Research and Treatment</i> , 2007 , 30, 169-74	2.8	8
38	Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. <i>BMC Palliative Care</i> , 2016 , 15, 25	3	7
37	Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. <i>BMC Cancer</i> , 2013 , 13, 75	4.8	7

36	Challenges in the multidisciplinary management of stage IV colon and rectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 317-26	4.2	7
35	Personalized treatment of colorectal cancer. <i>Onkologie</i> , 2012 , 35 Suppl 1, 42-8		7
34	Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e644-6	2.2	7
33	Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. <i>Annals of Surgical Oncology</i> , 2014 , 21, 1352-60	3.1	6
32	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1173-8	3.5	6
31	Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 144-52	5.4	5
30	Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e733-e739	3.8	5
29	Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study. <i>Radiation Oncology</i> , 2012 , 7, 83	4.2	5
28	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102226	14.4	5
27	Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. <i>Oncology Research and Treatment</i> , 2005 , 28, 482-8	2.8	4
26	Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 102202	4.9	4
25	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102202	14.4	4
24	Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Oncology Research and Treatment</i> , 2017 , 40, 21-26	2.8	3
23	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 557-71	3.5	2
22	Critical evaluation of the scientific content in clinical practice guidelines. <i>Cancer</i> , 2015 , 121, 1907-8	6.4	2
21	Multimodale Therapiestrategien bei Lebermetastasen kolorektaler Karzinome. <i>Viszeralmedizin</i> , 2011 , 27, 8-8		2
20	The role of peri-operative treatment in resectable liver metastases of colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 389-98	5.4	2
19	Reply to O. Gires et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e241-e242	2.2	2

18	Assessing the role of combination therapy in mCRC. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 5-11	1.6	2
17	Chemotherapy in rectal cancer. <i>European Journal of Cancer, Supplement</i> , 2005 , 3, 389-400	1.6	2
16	Continuation of regional chemotherapy of hepatic neoplasms despite occlusion of the hepatic artery-report of four cases. <i>Anti-Cancer Drugs</i> , 2002 , 13, 663-9	2.4	2
15	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	2
14	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 951-964	3.5	1
13	Oxaliplatin for colorectal cancer: recent evidence from clinical trials. <i>Colorectal Cancer</i> , 2013 , 2, 135-144	0.8	1
12	Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastasis: What is the Evidence?. <i>Current Colorectal Cancer Reports</i> , 2011 , 7, 180-186	1	1
11	Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. <i>Onkologie</i> , 2008 , 31, 464-7		1
10	Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 520-520	2.2	1
9	Multimodality treatment of colorectal peritoneal metastasis with perioperative systemic chemotherapy, cytoreductive surgery (CRS), and HIPEC: First safety results of the COMBATAC trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA382-LBA382	2.2	1
8	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021 , 144, 281-290	7.5	1
7	Maintenance treatment in metastatic colorectal cancer - AuthorsReply. <i>Lancet Oncology, The</i> , 2015 , 16, e584-5	21.7	0
6	Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. <i>BMC Cancer</i> , 2013 , 13, 454	4.8	
5	Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access. <i>Onkologie</i> , 2012 , 35, 440-2		
4	Zwei Therapieschemata im Vergleich. <i>Info Onkologie</i> , 2012 , 15, 16-18		
3	Sequential or combination chemotherapy for a patient with mCRC?. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 2, S12-6	14.4	
2	Should bevacizumab be continued beyond progression in colorectal cancer?. <i>Current Colorectal Cancer Reports</i> , 2008 , 4, 139-143	1	
1	Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO past, present, and future <i>Onkologie</i> , 2022 , 28, 44	0.1	

